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OBJECTIVES: To evaluate resource utilization and direct costs
of care for patients treated with negative pressure wound therapy
(NPWT) compared to standard moist wound therapy (MWT) 
in the treatment of partial diabetic foot amputation wounds.
METHODS: 162 diabetic subjects with post-amputation ulcers
were enrolled into a sixteen-week, randomized clinical trial.
Patients randomized to NPWT (n = 77) received therapy with
dressing changes every 48 h. Control patients (n = 85) received
standard MWT according to consensus guidelines. Resource uti-
lization and procedures were analyzed using a standardized pro-
tocol. RESULTS: More surgical procedures were performed in
the MWT group versus the NPWT group (120 vs. 43, p < 0.001).
The average number of dressing changes performed per patient
was 118.0 (range 12–226) for MWT compared with 41 (range
6–140) for NPWT (p = 0.0001). The MWT group had an
average of 11 (range 0–106) outpatient treatment visits during
the study period compared with 4 (range 0–47) in the NPWT
group (p < 0.05). The average total direct cost per patient treated
for 8 weeks or longer (independent of clinical outcome) was
$27,270 and $36,096 in the NPWT and MWT group, respec-
tively (incremental cost difference = $8826). Proportionally, the
highest costs were related to inpatient stay, antibiotics and
wound dressing treatment (materials and staff). The average
total cost to achieve healing was $25,954 for NPWT patients (N
= 43) compared with $38,806 for the MWT (n = 33) group
(incremental difference = $12,852). CONCLUSION: Treatment
of diabetic wounds using NPWT compared to MWT was asso-
ciated with substantially lower resource utilization with regard
to outpatient visits, dressing changes, and surgical procedures.
Overall direct treatment costs were also substantially different as
treatment costs with NPWT were on average $8,800 less than
with MWT. In summary, this study revealed treatment with
NPWT resulted in a greater proportion of patients obtaining
wound healing at a lower overall cost of care.
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OBJECTIVES: Elevating drug copayments has been found to
negatively affect medication adherence among patients with
chronic illness. This study sought to assess the correlation
between prescription drug copayment and medication adherence
upon initiating insulin aspart pen therapy from previous
vial/syringe use among type 2 diabetes patients. METHODS: A
pre-post conversion design was adopted using an integrated
medical and pharmacy claims database from >50 managed care
plans in the United States. Adults diagnosed with type 2 diabetes
who converted to insulin aspart pen therapy (NovoLog®
FlexPen®) [ie, the index event] from either human or analog
insulin vials between July 2001 and December 2002 with no
prior use of FlexPen® for six months were identiﬁed and retro-
spectively analyzed. Association between post-index medication
adherence [medical possession ratio (MPR) ≥ 80%] and drug
copayment after adjusting for differences in baseline demo-
graphics, pre-index copayment, and clinical comorbidities and
complications was analyzed through a logistic regression model.
RESULTS: A total of 670 subjects were identiﬁed [mean age:45.7
years (SD:13.8 years)]. Drug copayments increased by approxi-
mately $2 ($13.2 vs. $11.0) after initiating FlexPen® compared
to pre-index vial/syringe use. Logistic regression model results
showed that individuals with higher drug copayments had a sig-
niﬁcantly lower medication adherence (MPR < 80%) as com-
pared to individuals with lower copayments. Odds of adherence
being ≥80% decreased by 17% among individuals with $21 and
above drug copayment [Odds Ratio: 0.83 (0.71–0.94); p < 0.05],
while the odds decreased by 10% among individuals with copay-
ments ranging from $11–$20 [Odds Ratio: 0.90 (0.80–0.99); p
< 0.05], as compared to individuals with drug copayments ≤$10.
CONCLUSION: Increased drug copayments were found to be a
barrier to improved medication adherence among type 2 diabetes
patients converting to insulin analog pen therapy. Implications
of copayment variation on health outcomes in relation to med-
ication adherence should be researched.
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OBJECTIVES: Outcomes in patients with type 2 diabetes 
may vary according to the type of pharmacotherapy. The study
examined the differences in medication adherence and the total
health care costs in patients with type 2 diabetes who switched
from oral anti-diabetic medications (OAD) to insulin vial/syringe
therapy vs. those who converted from OAD to insulin pen
therapy. METHODS: The study comprised of patients with 
type 2 diabetes who were enrolled in the North Carolina 
Medicaid program from September 24, 2001 to July 18, 2006.
Patients who switched from OAD to syringe (n = 1162) were
pair-matched with those who switched from OAD to pen 
group by age, total health care costs and diabetes related 
costs. All included patients had complete enrollment for 24
months of follow up. Multiple linear regression models were
used to predict the impact switching therapies on individual out-
comes (i.e. total health care costs and medication adherence) for
each cohort using propensity scores as covariates. The adjusted
means were calculated to determine the group differences across
different outcomes. RESULTS: Medication adherence was 
comparable for patients who switched to pen vs. syringe (53%
vs. 50% respectively). The total health care costs for patients 
on pen therapy was signiﬁcantly lower than those on syringe
insulin (($14,857.42 vs. $31,764.78 respectively; p < 0.001).
considerable costs savings with pen therapy were reﬂected in 
hospital costs (1195.93 vs. 4965.31 respectively; p < 0.01), clinic
costs ($1086.80 vs. $3685.17 respectively; p < 0.05), diabetes
related costs (7324.37 vs. 13,762.21 respectively; p < 0.01) 
and outpatient costs (7795.98 vs. 13,103.51 respectively; p <
0.01). CONCLUSION: Even though medication adherence was
similar in both the groups, switching to pen therapy reﬂected sig-
niﬁcant reduction in health care services utilizations and associ-
ated costs. Health care professionals and policy makers should
consider initiating pen therapy in patients who fail to respond to
OADs.
